Raymond J. Grant

Experience

• Represented the lead underwriters in the $1.7 billion initial public offering of Elanco Animal Health Incorporated and the dealer managers in the $8.6 billion exchange of Elanco stock for Lilly stock
• Represented PQ Group Holdings Inc., a portfolio company of CCMP, in its $500 million initial public offering
• Represented the lead underwriters in the $56 million initial public offering of CRISPR Therapeutics AG and subsequent $114 million and $200 million follow-on equity offerings
• Represented the lead underwriters in the $69 million initial public offering of Unum Therapeutics Inc.
• Represented the lead underwriters in the $95 million initial public offering of AveXis, Inc.
• Represented Bain Capital Life Sciences in its convertible preferred stock PIPE investment in Dicerna Pharmaceuticals, Inc.
• Represented Bright Horizons Family Solutions, and its private equity sponsor Bain Capital, in multiple secondary offerings
• Represented Sarepta Therapeutics, Inc. in its $375 million follow-on equity offering
• Represented Medtronic plc in connection with its $1.3 billion acquisition of HeartWare International
• Represented IMS Health Holdings, Inc. in multiple 144A debt financings
• Represented the lead underwriters in follow-on equity offerings of bluebird bio, Inc. and Sage Therapeutics, Inc.